All articles tagged with #weight management
A cross-sectional study of 2,264 adults from the Northern Finland Birth Cohort finds higher habitual coffee intake is associated with lower total and visceral fat and greater skeletal muscle mass, plus metabolic and sex-hormone pattern differences between men and women; the study does not establish that coffee causes these changes.
Early-stage studies suggest obesity drugs may help manage PMOS, a hormonal disorder, offering hope to affected families; further research is needed to confirm effectiveness and safety.
Britain’s MHRA approved Eli Lilly’s Foundayo (orforglipron) for weight management and type 2 diabetes, marking Lilly’s first European license for the oral GLP-1 drug. The EU decision is not expected until next year. An NHS coverage decision will be made by NICE on November 18, with initial access likely in the private market; Novo Nordisk’s Wegovy pill is expected to reach EU markets soon, increasing competition. The UK remains the only country with a bilateral deal with the US to pay more for medicines.
A University of Toronto study followed 74 overweight adults for 12 weeks and found that three daily servings of full-fat dairy did not cause weight gain or cholesterol increases; participants even showed lower blood pressure and higher intake of calcium, protein, and vitamin D, supporting a 'dairy matrix' view that the health effects come from the whole dairy structure rather than isolated nutrients.
Experts say GLP-1 weight-loss drugs can help, but weight is often regained after stopping. Long-term success depends on building sustainable eating and exercise habits with a dietitian, rather than relying solely on medication. Side effects like slowed digestion and nausea may occur, so ongoing medical guidance is important.
A Perspective published in The Journal of Nutrition analyzes the updated 2025–2030 Dietary Guidelines' protein recommendation of 1.2–1.6 g/kg/day. It acknowledges strengths such as a focus on high‑quality protein and potential weight‑management benefits for those with overweight/obesity, but argues the current evidence does not justify a universal higher‑protein intake for all Americans and calls for more diverse research across life stages and populations to strengthen future guidance.
A six‑week analysis cited in Annals of Internal Medicine shows that cutting about 80 minutes of sleep per night can cause roughly 0.45 kg (1 lb) weight gain, larger waistlines, and more sedentary behavior—even with a healthy diet and exercise. Dr. Sudhir Kumar emphasizes that sleep is a third pillar of weight management alongside diet and exercise, and most adults should aim for seven to nine hours of quality sleep nightly to protect metabolism, heart, and brain.
The American Heart Association coined CKM syndrome in 2023 to describe the overlap of cardiovascular, kidney, and metabolic diseases driven by excess weight, high blood pressure, and high blood sugar. It’s defined as a four‑stage continuum (Stage 0–Stage 4) with about 90% of Americans on the spectrum; prevention focuses on lifestyle changes (Mediterranean-style diet, physical activity, sleep, avoiding nicotine) and broad‑acting medications (GLP‑1s, SGLT2 inhibitors, nsMRAs) alongside traditional treatments like metformin, statins, and ACE inhibitors to slow progression and reduce hospitalizations. The overarching message is awareness and prevention, rather than overmedicalizing those at risk—including Stage 0 individuals who are at risk but not yet diseased.
Beginning Wednesday, Medicare will temporarily cover GLP-1 weight-loss drugs for seniors and certain disabled beneficiaries through an 18-month pilot, with a $50 monthly copay; coverage requires prior authorization and the program’s costs to taxpayers have not been disclosed. Covered drugs include Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy (including the Wegovy pill Foundayo). The move aims to curb obesity-related health risks but raises questions about long-term affordability and access.
Intermittent fasting is not a weight-loss diet but a structured eating window that rests the digestive system, reduces inflammation, and may improve insulin sensitivity, blood sugar, sleep, and mental energy; however, weight loss still depends on total calories and diet quality, and fasting isn’t ideal for athletes or during healing—use a consistent 8–12 hour window and tailor to your health needs.
An NIH-supported PATHWEIGH program implemented across 56 UCHealth primary care clinics and reaching about 274,000 patients reduced population weight gain by 0.58 kg over 18 months, increased weight-related care by 23%, and is being considered as a standard approach to obesity treatment in the U.S.
A nutritionist explains that regularly eating large meals close to bedtime can disrupt the circadian rhythm, impair insulin sensitivity, and reduce sleep quality, potentially complicating long‑term weight management. However, outcomes depend on total calories, food quality, sleep, stress, and activity, so a sustainable approach is to eat a balanced dinner a few hours before bed and avoid fear‑based rules.
A study of more than 38,000 women around menopause (published May 20 in JAMA Network Open) links plant-forward eating—rich in fruits, vegetables, whole grains, nuts and legumes and low in processed meats, salt, and ultra-processed foods—with less weight gain and lower obesity risk during the menopausal transition. Diet patterns such as the Mediterranean, DASH, and especially the Planetary Health Diet offered the strongest protection, while ultra-processed foods and high-insulin-raising diets predicted more gain. Experts advise adding plant foods you enjoy to meals, boosting fiber, and limiting processed items; supplements (B12, D) and dietitian guidance may help for fully plant-based plans.
In the TRIUMPH-1 Phase 3 trial, Lilly’s triple hormone agonist retatrutide produced clinically meaningful weight loss across all dose groups over 80 weeks: 12 mg yielded an average 70.3 lb loss (28.3%) with 45.3% achieving ≥30% weight reduction, and 65.3% reached BMI 22 at Week 80; 9 mg achieved 64.4 lb (25.9%) and 4 mg 47.2 lb (19.0%). An extension up to 104 weeks showed continued weight loss in some participants, including those with higher baseline BMI. The data support retatrutide’s potential as a non-surgical obesity treatment, with detailed safety labeling included in the release.
Randomised trials show that replacing sugar with approved sweeteners can lower post-meal glucose and insulin and aid weight maintenance in structured diets; there is no universal substitute that perfectly mimics sugar's bulk and mouthfeel, and policy debates continue to hinge on differences between observational studies and trials. Future advances may come from blends, sweet proteins, rare sugars, and AI-assisted discovery, but more data across children and high-risk groups are needed.